Form 4: Bioadaptives Director Frissora Boosts Stake with Preferred Stock

Bioadaptives Director Mark P. Frissora acquired Series D Convertible Preferred Stock as compensation for board services, increasing his beneficial ownership.

Summary

• Mark P. Frissora, a Director of BIOADAPTIVES, INC. (BDPT), acquired 2,286 shares of Series D Convertible Preferred Stock.
• These shares were issued as compensation for board services, pursuant to a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation.
• Conversion of these shares is restricted for six months from the issuance date, except in the case of liquidation, where conversion occurs immediately.
• Each Series D Convertible Preferred Stock share carries 100 votes on matters of the Issuer, irrespective of the beneficial ownership limitation.
• The right to convert the preferred stock into common stock does not expire.
• Following this transaction, Mark P. Frissora beneficially owns 57,217 shares of Series D Convertible Preferred Stock directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director receiving equity compensation and increasing their stake aligns their interests with shareholders and can be interpreted as a vote of confidence in the company's future.

Positives

• A director receiving compensation in company stock and increasing their beneficial ownership can signal confidence in the company's future performance and aligns management interests with shareholders.

Future Outlook

The Series D Convertible Preferred Stock acquired by the director is convertible into common stock at a 100:1 ratio, subject to a 4.9% beneficial ownership limitation, and becomes exercisable six months post-issuance, indicating a future potential increase in common stock holdings.

Industry Context

This Form 4 filing reflects a routine insider transaction where a director receives equity as compensation for services. Such transactions are common across industries and are closely watched by investors for signals regarding management's alignment and confidence in the company's prospects.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The acquisition of Series D Convertible Preferred Stock by Director Mark P. Frissora as compensation for board services constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's increased equity stake as a positive signal, indicating management's commitment and belief in the company's future.
• Board of Directors: The compensation structure reinforces alignment between board members and the company's long-term performance.

Next Steps

• The Series D Convertible Preferred Stock will become convertible into common stock starting July 1, 2026, allowing the director to potentially increase their common stock holdings.

Key Dates

Keywords

Bioadaptives, BDPT, Form 4, Insider Transaction, Director Compensation, Convertible Preferred Stock, Mark P. Frissora, Equity Compensation